April 1st 2025
Novavax’s COVID-19 vaccine, Merck’s RSV antibody, and Innoviva’s gonorrhea antibiotic await regulatory decisions this quarter.
The Importance of Regular Viral Load Testing in HIV-Positive Individuals
December 27th 2016The 90-90-90 goal from the Joint UN Programme on HIV/AIDS has three prongs: By 2020, 90% of people with HIV worldwide will be aware of their status; 90% of HIV+ people will have access to treatment; and 90% of those with HIV will have a suppressed viral load. Money and training are key.
Read More
Will Cabotegravir be a Game-changer in HIV Prevention?
December 23rd 2016The first large-scale clinical trial of a new HIV preventive drug, cabotegravir, has been launched and researchers are looking to see if it is just as effective as Truvada, the only licensed PrEP regimen currently available.
Read More
New Study Links Rates of Male Circumcision to HIV-2 Prevalence
December 15th 2016Male circumcision has been promoted by public health officials as a way of reducing HIV-1 infection rates, and now, the first study of its kind shows that circumcision rates have also impacted the spread of HIV-2 in West Africa.
Read More
Epidemic Strains of Syphilis Have a Common and Recent Ancestor
December 15th 2016As rates of syphilis have gone up around the world, a team of researchers from the University of Zurich have found that today’s epidemic strains have shared origins and emerged after the discovery of antibiotics.
Read More
New Implantable Device Can Revolutionize Treatment of HIV, Cancer, and Other Diseases
December 15th 2016A dynamic partnership has resulted in the development of a new, minimally-invasive device that can be used to treat HIV, cancer, and a number of other disease, ensuring medicinal adherence.
Read More